Multifocal diffractive add-on IOL suitable alternative

Article

Multifocal diffractive add-on IOL is a suitable alternative to standard multifocal IOLs for sulcus fixation.

Multifocal diffractive add-on IOL is a suitable alternative to standard multifocal IOLs for sulcus fixation.

The prospective controlled clinical trial, led by Dr Jens Schrecker, Department of Ophthalmology, Saarland University, Homburg/Saar, Germany, included 65 eyes of 37 patients.

Of the patients studied, 34 eyes of 20 patients underwent phacoemulsification and implantation of a monofocal IOL in the capsular bag and an additional aberration-free diffractive IOL in the ciliary sulcus. The remaining 31 eyes of 17 patients were fitted with an aberration-correcting diffractive posterior chamber IOL.

Outcome measurements included uncorrected and distance-corrected distance, intermediate, and near visual acuities; contrast sensitivity and defocus curve were performed three months postoperatively.

There were no complications with cataract surgery, IOL implantation or the postoperative course. There were no significant differences in uncorrected and distance-corrected distance, intermediate, or near visual acuities between the two groups.

In both groups the median uncorrected distance visual acuity was 0.00 logMAR uncorrected near visual acuity was 0.10 logMAR. Contrast sensitivity testing was significantly better in the multifocal add-on IOL group, namely at spatial frequencies over 1.5 cycles per degree. The overall visual performance with a multifocal diffractive add-on IOL was equivalent to that obtained with the multifocal diffractive PC IOL.

The abstract can be viewed in the latest edition of the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.